International Journal of Hematology

, Volume 76, Issue 3, pp 284–286 | Cite as

Late Response to Cyclosporine in Refractory Thrombotic Thrombocytopenic Purpura

  • Annamaria Nosari
  • Patrizia Bernuzzi
  • Roberto Corneo
  • Ester Pungolino
  • Giuliana Muti
  • Valentina Rossi
  • Enrica Morra
Case Report

Abstract

Plasma exchange (PEX) with fresh frozen plasma, usually in association with steroid therapy, has been shown to be the firstline treatment of thrombotic thrombocytopenic purpura. It works by removing ultralarge von Willebrand factor (vWF) multimers and inhibitory antibody and by supplying normal protease. For patients with disease refractory to PEX, there is no standardized treatment. Limited and sporadic success with different therapies (vincristine sulfate, prostacyclin, intravenous immunoglobulins, splenectomy) has been described. We report the case of a woman who developed refractory disease after an initial response to PEX and despite a very high number of PEX procedures performed. Low activity (<5%) of serum vWF-cleaving protease and a low level of protease inhibitor were documented. The patient had a slow but sustained response when oral cyclosporine was administered concomitantly with PEX, which was slowly tapered. The activity of serum vWF-cleaving protease normalized. At relapse, treatment with cyclosporine, added after the failure of steroids and PEX, led to a lasting response. It is possible that in some cases cyclosporine therapy must be of particularly long duration before being considered ineffective.Int J Hematol. 2002;76:284-286.

Key words

Thrombotic thrombocytopenic purpura Refractory Cyclosporine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Furlan M, Robles R, Galbusera M, et al. von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome.N Engl J Med. 1998;339:1578–1584.CrossRefPubMedGoogle Scholar
  2. 2.
    Tsai HM, Lian EC. Antibodies to von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura.N Engl J Med. 1998;339:1585–1594.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    van Ojik H, Biesma DH, Fijnheer R, et al. Cyclosporine for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation.Br J Haematol. 1997;96:641–643.CrossRefPubMedGoogle Scholar
  4. 4.
    Kierdorf H, Maurin N, Heintz B. Cyclosporine for thrombotic thrombocytopenic purpura.Ann Intern Med. 1993;118:987–988.CrossRefPubMedGoogle Scholar
  5. 5.
    Bachman TC. Refractory thrombotic thrombocytopenic purpura treated with cyclosporine.Am J Hematol. 1996;51:93–94.CrossRefPubMedGoogle Scholar
  6. 6.
    Hand JP, Lawloe ER,Yong CKK, Davis JK. Successful use of cyclosporine A in the treatment of refractory thrombotic thrombocytopenic purpura.Br J Haematol. 1998;100:597–599.CrossRefPubMedGoogle Scholar
  7. 7.
    Gable PS, Smith WS, Millard FE. Cyclosporine in relapsed thrombotic thrombocytopenic purpura.Blood. 1993;82:604a.Google Scholar
  8. 8.
    Pasquale D, Vidhya R, DaSilva K, Tsam MF, Lansing L, Chikkappa G. Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine.Am J Med. 1998;57: 57–61.Google Scholar
  9. 9.
    Kalhs P, Brugger S, Schwarzinger I, et al. Microangiopathy following allogeneic marrow transplantation: association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.Transplantation. 1995;60:949–957.CrossRefPubMedGoogle Scholar
  10. 10.
    Paquette RL, Tran L, Landaw EM. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis.Bone Marrow Transplant. 1998;22:351–357.CrossRefPubMedGoogle Scholar
  11. 11.
    Pettitt AR, Clarck RE. Thrombotic microangiopathy following bone marrow transplantation.Bone Marrow Transplant. 1994;14: 495–504.PubMedGoogle Scholar
  12. 12.
    Dzik WK, Georgi BA, Khettry U, Jenkins RL. Cyclosporine-associated thrombotic thrombocytopenic purpura following liver transplantation: successful treatment with plasma exchange.Transplantation. 1987;44:570–572.CrossRefPubMedGoogle Scholar
  13. 13.
    Remuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine.Am J Kidney Dis. 1989;13:261–272.CrossRefPubMedGoogle Scholar
  14. 14.
    Bobbio-Pallavicini E, Centurioni R, Gugliotta L, et al. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma exchange.Eur J Haematol. 1994;52:222–226.CrossRefPubMedGoogle Scholar
  15. 15.
    Porta C, Caporali R, Montecucco C. Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects.Haematologica. 1999;84:260–269.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Annamaria Nosari
    • 1
  • Patrizia Bernuzzi
    • 1
  • Roberto Corneo
    • 2
  • Ester Pungolino
    • 1
  • Giuliana Muti
    • 1
  • Valentina Rossi
    • 1
  • Enrica Morra
    • 1
  1. 1.Department of Oncology and HematologyNiguarda Ca’ Granda HospitalMilanoItaly
  2. 2.Transfusion MedicineNiguarda Ca’ Granda HospitalMilanItaly

Personalised recommendations